Relationship between Total Lymphocyte count (TLC) and CD4 count among peoples living with HIV, Southern Ethiopia: a retrospective evaluation

Deresse Daka¹ and Eskindir Loha*²

Address: ¹Faculty of Medicine, Hawassa University, Hawassa, Ethiopia and ²Faculty of Public Health, Hawassa University, Hawassa, Ethiopia

Email: Deresse Daka - drsdk2000@yahoo.com; Eskindir Loha* - eskindir_loha@yahoo.com

* Corresponding author

Abstract

Background: CD4 count is a standard measure of immunodeficiency in adults infected with HIV to initiate and monitor highly active antiretroviral therapy; however, it may not be feasible in resource poor countries. There is a need to have another marker of immunodeficiency that is less resource demanding.

Objective: The objective of this study was to assess the relationship between total lymphocyte count and CD4 count in one of the resource poor countries, Ethiopia.

Methods: This was a retrospective evaluation. A total of 2019 cases with total lymphocyte and CD4 counts from three hospitals (Yirgalem, Hossana and Arba-Minch) were included in the study. Pearson correlation, linear regression and Receiver Operating Characteristic (ROC) were used.

Result: For adults, the sensitivity, specificity, positive and negative predictive values of TLC < 1200 cells/mm³ to predict CD4 count < 200 cells/mm³ were 41%, 83.5%, 87.9% and 32.5%, respectively. For subjects aged less than 18 years, these values were 20.2%, 87%, 82% and 27.1%, respectively. A TLC ≤ 1780 cells/mm³ was found to have maximal sensitivity (61%) and specificity (62%) for predicting a CD4 cell count of < 200 cells/mm³. Meanwhile, a TLC ≤ 1885 cells/mm³ would identify only 59% of patients with CD4 count of < 350 cells/mm³ (sensitivity, 59%; and specificity, 61%). The combined sensitivity and specificity for patients above 40 years of age was greater.

Conclusion: Our data revealed low sensitivity and specificity of TLC as a surrogate measure for CD4 count.

Background

It is estimated that 32.2 million people worldwide were living with HIV at the end of 2007. Meanwhile, 2.1 million lost their lives to AIDS, and 2.5 million became newly infected with HIV in the same year [1]. The proportion of people who have become infected with HIV is believed to have peaked in the late 1990s and stabilized subse-
to address the problem, scarcity of CD4 counter to initiate highly active antiretroviral therapy (HAART), for instance. The determination of CD4 count has become a standard measure of immunodeficiency in adults infected with HIV in resource rich areas where the burden of the pandemic is low [3]. Cognizant of this problem, the current guidelines from World Health Organization (WHO) acknowledge that total lymphocyte count (TLC) may be used to make treatment decision in resource poor settings when CD4 count is not available and patients are mildly symptomatic [4].

The rationale for the WHO's recommendation is that most studies concluded a decline in TLC was strongly correlated with a decline in CD4 count, though there were some discrepancies [5-10]. On the other hand, there is a recent report warned that TLC < 1200 cells/mm³ was not optimal for identifying patients requiring HAART since it showed low sensitivity and specificity to predict CD4 count below 200 cells/mm³ [10,11]. This necessitates further study on the relationship between TLC and CD4. Therefore, the objective of this research was to assess the relationship between total lymphocyte count (TLC) and CD4 count in one of the resource poor countries, Ethiopia.

**Methods**

A retrospective evaluation was carried out in three hospitals (Yirgalem, Arba-Minch and Hossana) in the southern part of Ethiopia. Collating data was burdensome as we reviewed 3120 antiretroviral treatment (ART) and pre-ART cards (Yirgalem); 2180 ART and pre ART cards (Arba-Minch); and more than 20 000 non-ART, ART and pre-ART cards (Hossana). The total number of cases with complete data on TLC and CD4 counts was 2019 of which 750, 650 and 619 were from Yirgalem, Arba-Minch and Hossana hospitals, respectively. The year of the data extends from 2003 to 2008. All cases were hospital patients. In all hospitals, TLC and CD4 counts were determined using Cell Dyne automated machine from ABBOTT, USA.

SPSS 15 was used to analyze the data. Linear regression was carried out. As the CD4 and TLC values were log transformed to maintain normality, 100(e^{\beta_1} - 1)[12] was used to interpret the regression coefficient $\beta$ and expressed as percentage points. Pearson correlation coefficient was also reported.

Receiver Operating Characteristic (ROC) was used to determine the cut-off points with best sensitivity and specificity combination. Area under the ROC curve (AUC) was also used to compare the combined sensitivity and specificity among different categories of the study subjects.

Ethical clearance was obtained from College of Health Sciences, Hawassa University-Institutional Ethical Review board, and permission was sought from each hospital.

**Results**

A total of 2019 subjects were included in this study, among which 1064 (53%) were females. The mean (standard deviation) age was 32.4 (9.4) years (ranging from 5–65 years), and the majority, 1707 (85%) were below the age of 40 years. Three fourth of the study subjects had CD4 count less than 200 cells/mm³ and 97% had a count of less than 350 cells/mm³. The mean (standard deviation) of CD4 and TLC counts were 1453.1 (942.9) cells/mm³ and 1734.1 (880.9) cells/mm³ for subjects aged 18 years and above, and for those under the age of 18 years, the figures were 2003.4 (170.6) cells/mm³ and 3700 (942.9) cells/mm³, respectively.

The correlation coefficient $r$ for lnCD4 and lnTLC was .398 ($p < .001$). The linear regression coefficient ($\beta$) was 0.61; that is for each 1% increase in TLC there was 0.61% increase in CD4 count. However, the model was capable of explaining only 16% (coefficient of determination-$R^2$ adjusted) of the variation. Figure 1 shows the relationship between CD4 and TLC counts using the original scales of measurement ($R^2 = 0.1$, $r = 0.33$, $p < 0.001$).

Mean CD4, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for different levels of TLC cut-off values among those who were less than 18 years of age and adults are depicted in table 1.

Considering the best cut-off values of TLC, that are with the highest sensitivity and specificity combinations, a TLC ≤ 1780 cells/mm³ was found to have maximal sensitivity (61%) and specificity (62%) for predicting a CD4 cell count of < 200 cells/mm³. Meanwhile, a TLC ≤ 1885 cells/mm³ would identify only 59% of patients with CD4 count of < 350 cells/mm³ (sensitivity, 59%; and specificity, 61%). The combined sensitivity and specificity for patients above 40 years of age was greater since their ROC curve AUC 0.72 was greater as compared to 0.64 of patients ≤ 40 years; the AUC was also slightly greater for female sex (0.66 versus 0.65). For subjects aged less than 18 years the best TLC cut-off was 2050 with sensitivity and specificity of 53.2% and 52.2%, respectively. The ROC curve (Figure 2) showed a fairly poor separation between classes (the diagonal reference line represents random performance).

**Discussion**

According to the WHO's general principle to guide decision making about when to initiate ART in resource poor setting, a wider availability of CD4 testing is indispensable. However, the scarcity of this technology shouldn't be
Figure 1
Relationship between CD4 and TLC counts.

Table 1: Different cut-off values of TLC predicting CD4 < 200 cells/mm³ for subjects aged 18 years and above, and less than 18 years.

| TLC cut-off values (cells/mm³) | Mean CD4 (cells/mm³) | Sensitivity | Specificity | PPV    | NPV    |
|-------------------------------|----------------------|-------------|-------------|--------|--------|
|                               | < 18                 | ≥ 18        | < 18        | ≥ 18   | < 18   | ≥ 18   | < 18   | ≥ 18   |
| 1000                          | 134.5                | 86.6        | 14.9        | 21.8   | 87.0   | 95.3   | 77.0   | 93.2   | 25.8   | 29.3   |
| 1200                          | 150.1                | 99.2        | 20.2        | 41.0   | 87.0   | 83.5   | 82.0   | 87.9   | 27.1   | 32.5   |
| 1400                          | 138.1                | 112.4       | 24.5        | 51.2   | 87.0   | 74.5   | 84.6   | 85.5   | 28.2   | 34.2   |
| 1600                          | 144.9                | 118.8       | 31.1        | 57.3   | 84.8   | 65.5   | 87.1   | 83.0   | 30.8   | 34.3   |
| 1800                          | 148.9                | 124.0       | 40.4        | 63.9   | 78.3   | 55.7   | 84.5   | 80.9   | 30.9   | 34.5   |
| 2000                          | 162.4                | 130.5       | 47.9        | 71.7   | 56.5   | 45.9   | 76.4   | 79.6   | 27.0   | 35.6   |
| 2200                          | 190.3                | 132.9       | 59.6        | 74.5   | 39.1   | 42.0   | 74.2   | 79.1   | 24.8   | 36.0   |
a cause to deter treatment while the patient's condition deteriorates if there is access to TLC and knowledge of clinical staging [4]. Several studies revealed reasonably adequate sensitivity and specificity to consider TLC as a surrogate measure for CD4 [5-10].

Nevertheless, this study supports the notion by Gupta and colleagues (2007), as we observed low sensitivity and specificity of TLC as an alternate marker to initiate ART. In our study, the sensitivity and specificity of TLC < 1200 to predict CD4 count < 200 for adults were 41% and 83.5%, and these figures were lower than that reported recently from India, 59% and 94%, respectively [11]. As it was reported by Jacobson and colleagues (2003), TLC may still be used in resource limited area with the understanding of its low sensitivity and specificity. Stebbing and colleagues also indicated that despite minimally less reliability of TLC as a surrogate for CD4, TLC is important tool in the absence of expensive equipment to measure CD4 [13].

We recommend further exploration of available data to ameliorate such disparities of sensitivities and specificities of TLC as proxy for CD4 count or else keep on expansion of access to CD4 counter.

We also recommend inclusion of white blood cells, red blood cells, haemoglobin, hematocrit and platelets in such analyses and also separate analysis for pregnant women, which we considered as the limitations of this manuscript.

**Competing interests**

The authors declare that they have no competing interests.

---

**Figure 2**

ROC curve with sensitivity and 1-specificity of TLC cut-off values identifying a CD4 count of < 200 cells/mm³ (AUC = .66).
Authors’ contributions
DD wrote the proposal, secured the funding and organized the data collection. EL analysed and interpreted the data and developed the manuscript. Both authors read and approved the final manuscript.

Acknowledgements
We thank Hawassa University Research and Extension Office for the financial support. We also express our gratitude to Yirgalem, Arba-Minch and Hossana Hospital staffs for facilitating the data collection.

References
1. UNAIDS, WHO: AIDS epidemic update. Geneva 2007.
2. UNAIDS: Report on The Global AIDS Epidemic: Executive summary, in A UNAIDS 10th anniversary special edition. Geneva 2006.
3. Ammann A, Burrowes S: Use of Total Lymphocyte Count vs CD4 Cell Count as a Marker of Immunity in HIV-Infected Adults and Children: Women, Children, and HIV; Resources for Prevention and Treatment. 2006 [http://www.womenchildrenhiv.org/wchiv/page=tp-02-031]. (accessed on 25 June 2008).
4. WHO: Antiretroviral drugs for the treatment of HIV infection in adults and adolescents in resource-limited settings. Recommendations for a Public Health Approach (2005–2006 Revision): Brief Meeting Report. Guidelines Developing Group 2005.
5. Bedell R, Heath K, Hogg R, Wood E, Press N, Yip B, O'Shaughnessy M, Montaner J: Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings. Antivir Ther 2003, 8:379-384.
6. Ledergerber B, Lundgren J, Walker A, Sabin C, Justice A, Reiss P, Mussini C, Wic F, Monforte AD, Weber R, et al: Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004, 364:51-62.
7. Anastos K, Shi Q, French A, Levine A, Greenblatt R, Williams C, DeHovitz J, Delapenha R, Hoover D: Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004, 35:383-392.
8. Anastos K, Barrón Y, Cohen M, Greenblatt R, Minkoff H, Levine A, Young M, Gange S: The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med 2004, 140:256-264.
9. Spacek L, Griswold M, Quinn T, Moore R: Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings. AIDS 2003, 17:1311-1317.
10. Jacobson MA, Liu L, Khayam-Bashi H, Deeks SG, Hecht FM, Kahn J: Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy. AIDS 2003, 17:917-919.
11. Gupta A, Gupta N, Bhosale R, Kakrani A, Kulkarni V: Low sensitivity of total lymphocyte count as a surrogate marker to identify antepartum and postpartum Indian women who require antiretroviral therapy. JAIDS 2007, 46:338-342.
12. Vittinghoff E, V Glidden D, C Shiboski S, E McCulloch C: Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models First edition. Springer: 2005.
13. Stebbing J, SawleshwarKar S, Michailidis C, Jones R, Bower M, Mandala S, Nelson M, Gazzard B: Assessment of the efficacy of total lymphocyte counts as predictors of AIDS defining infections in HIV-1 infected people. Postgraduate Medical Journal 2005, 81:586-588.

Publish with BioMed Central and every scientist can read your work free of charge
"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
• available free of charge to the entire biomedical community
• peer reviewed and published immediately upon acceptance
• cited in PubMed and archived on PubMed Central
• yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp